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Abstract
Background: Commercial bacterins are widely used at weaning to control Mycoplasma hyopneumoniae infections
in pigs. However, it is not known whether the efficacy of vaccinating against M. hyopneumoniae can be influenced
by the weaning process when vaccination is applied at the day of weaning. The present study assessed the efficacy
of a single M. hyopneumoniae vaccination (Ingelvac MycoFLEX®) three days before weaning (V1) or at weaning (V2)
against experimental challenge infection. Four weeks after vaccination, groups V1 and V2 (n = 20 pigs each)
and a non-vaccinated, positive control group (PCG) (n = 20) were endotracheally inoculated with a virulent
M. hyopneumoniae field strain. Five pigs were used as a negative control group. All pigs were euthanized
5 weeks after challenge. The main parameters investigated included macroscopic and histopathological lung
lesions at necropsy, immunofluorescence (IF) staining and quantitative real-time PCR (qPCR) on broncho-alveolar
lavage (BAL) fluid for quantifying M. hyopneumoniae.
Results: The average macroscopic lung lesion scores in groups V1, V2 and PCG were 0.54, 0.88 and 1.04, respectively
(P > 0.05). The average lymphohistiocytic infiltration scores in groups V1, V2 and PCG were 2.95, 3.16 and 3.61,
respectively (P < 0.05). The average IF scores were: V1 = 1.13, V2 = 1.19 and PCG = 1.25 (P > 0.05), the qPCR
values were: V1 = 102.94, V2 = 102.76 and PCG = 103.23 (P > 0.05). All pigs of the negative control group remained
negative throughout the study.
Conclusions: Both vaccinated groups had lower numbers of macroscopic and histopathological lung lesions,
and lower numbers of M. hyopneumoniae organisms in the BAL fluid compared to the PCG. However, no firm
conclusions could be made on whether weaning negatively influences the efficacy of M. hyopneumoniae
vaccination, since significant differences between the treatment groups were only obtained for the histopathological
lung lesions. This could be attributed to the fact that milder macroscopic lung lesions were produced in the inoculated
pigs, when compared to previous trials conducted by the same group. Further research under field conditions is
warranted to assess possible differences between the two vaccination strategies.
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Background
Mycoplasma hyopneumoniae is the etiological agent of
enzootic pneumonia (EP), a chronic respiratory disease
affecting mainly grow-finishing pigs [1, 2]. M. hyopneu-
moniae infections have been detected in almost all
countries with intensive production systems and are
responsible for major economic losses in the pig in-
dustry [1, 3]. These economic losses are due to pig
growth retardation, higher feed conversion ratios, in-
creased antimicrobial use and increased susceptibility
to other respiratory pathogens such as Pasteurella
multocida, Actinobacillus pleuropneumoniae, Trueper-
ella pyogenes and Streptococcus suis [4]. M. hyopneu-
moniae is also an important pathogen involved in the
porcine respiratory disease complex (PRDC) [5, 6].
Control ofM. hyopneumoniae infections can be achieved
in a number of ways, such as optimizing management and
housing conditions, antimicrobial medication and vaccin-
ation. In many countries, more than 70 % of pig herds
are vaccinated against M. hyopneumoniae in an effort
to control the disease [7]. Vaccination with commercial
bacterins has been extensively proven to reduce per-
formance losses, the severity of clinical signs and lung
lesions [8–12]. Different vaccination schemes can be
implemented, depending on the type of herd, the pro-
duction system, the infection pattern and the preference
of the farmer.
Currently, both double and single vaccination strat-
egies are widely practiced. Single vaccination is often
administered either at 1 week of age or at weaning.
Vaccination is often done at weaning because the pig-
lets are handled then anyway, so vaccination can eas-
ily be included in routine farm management practices
[12, 13]. On the other hand, weaning is one of the
most stressful events in the pig’s life [14, 15]. The
piglets are then experiencing the abrupt separation
from the sow, they are being handled, they are being
moved to other facilities, they are usually being mixed
with other pigs, and they are receiving a different type
of feed [14, 15]. Stress may interfere with an optimal
response to vaccination, and therefore it is generally
recommended not to vaccinate animals that are se-
verely stressed [16].
Consequently, one important question that remains
to be answered, and whose answer could contribute
to the optimization of existing vaccination schemes,
is whether the efficacy of vaccinating against M.
hyopneumoniae can be influenced by the weaning
process when vaccination is applied at the day of
weaning. The objective of this trial was to investigate
the efficacy of a one-shot vaccination applied either
at weaning or three days before weaning in pigs ex-
perimentally infected with a virulent M. hyopneumo-
niae field strain.
Results
Clinical and performance parameters
In total, two pigs died during the trial, after receiving the
endotracheal challenge infection (one in the V2 group
and one in the PCG group). These pigs were not in-
cluded in the analysis. In groups V1, V2 and PCG,
coughing started approximately six days after challenge
and continued to increase towards the end of the trial.
In groups V1 and V2, coughing peaked between 66 and
70 days of age, whereas in the PCG, the peak was
noticed at 80 days of age. The respiratory disease score
(RDS) values for the period before challenge and the
period after challenge, as well as for the overall period,
are shown in Table 1. There were no significant differ-
ences between the groups (P > 0.05).
The average daily weight gain (ADG) results of groups
V1, V2 and PCG during the period before challenge and
during the period after challenge, as well as during the
overall period, are presented in Table 2. There were no
significant differences (P > 0.05) between the groups.
Macroscopic and histopathological lung lesions, and IF
testing for M. hyopneumoniae
Only numerical differences in macroscopic lung lesions
(P > 0.05) were found between groups V1, V2 and PCG
(Table 3). The lowest average macroscopic lung lesion
score was given to group V1 (0.54). The average lung
lesion scores of the pigs in groups V2 and PCG were
0.88 and 1.04, respectively. There were no macroscopic
lung lesions in the negative control group.
Statistically significant differences (P < 0.05) in histo-
pathological lung lesions were present between groups
V1, V2 and PCG (Table 3). The average lymphohistio-
cytic infiltration score was lower in group V1 (2.95)
when compared with groups V2 (3.16) and PCG (3.61).
The V1 group had the highest average percentage of air
in the lung tissue (44.28), followed by group V2 (37.47)
and PCG (31.46).
The results from the IF testing that was used to semi-
quantitatively assess the load of M. hyopneumoniae
organisms in the lung tissue, namely 1.13 (group V1),
Table 1 Average (± standard deviation) of the daily RDS of the
pigs for the three different periods
Age range (days) V1 (n = 20) V2 (n = 19) PCG (n = 19) P value
29–47 0.07 ± 0.26 0.28 ± 0.69 0.11 ± 0.37 0.108
48–83 0.79 ± 1.30 0.62 ± 1.20 0.65 ± 1.19 0.626
29–83 0.54 ± 0.94 0.50 ± 1.03 0.47 ± 0.91 0.852
Scores ranged from 0 (no coughing) to 6 (severe coughing undisturbed)
(Halbur et al. [29]). Treatment groups: V1 (vaccinated before weaning, at
18 days of age), V2 (vaccinated on the day of weaning, at 21 days of age)
and PCG (non-vaccinated). Overall and pairwise comparisons did not reveal
any significant differences between groups for the three different periods.
D48: experimental infection, D83: euthanasia
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1.19 (group V2) and 1.25 (PCG), were not significantly
different (P > 0.05) between groups (Table 3). All pigs of
the negative control group were negative for IF staining.
qPCR assay and bacteriological examination
The number of M. hyopneumoniae organisms quantified
by qPCR in the BAL fluid was not significantly different
(P > 0.05) between groups V1, V2 and PCG (Table 3).
Lower numbers of organisms were detected in groups V1
and V2 (102.94 and 102.76 copies/mL, respectively) com-
pared to group PCG (103.23 copies/mL). No M. hyopneu-
moniae DNA was detected in pigs of the negative control
group.
Several bacteria were isolated from BAL fluid. In
groups V1 and V2, Bordetella bronchiseptica (V1: 3/20
pigs; V2: 1/20 pigs) and polybacterial cultures (V1: 4/20
pigs; V2: 2/20 pigs) were obtained. In the PCG, Haemoph-
ilus parasuis (1/20 pigs), S. suis (1/20 pigs) and polybacter-
ial cultures (1/20 pigs) were obtained. The bacteriological
culture remained negative for all pigs in the negative
control group.
Serology
The serological results for M. hyopneumoniae at 21, 48
and 83 days of age are presented in Table 4. At 21 days
of age, all the piglets were serologically negative for M.
hyopneumoniae. At 48 days of age, 40 % of the pigs in
each of the vaccinated groups V1 and V2 had serocon-
verted. None of the pigs in the PCG had seroconverted
to M. hyopneumoniae at that time. At 83 days of age, all
the pigs in groups V1 and V2 were seropositive, while
95 % of the pigs in the PCG had seroconverted. All pigs
in the negative control group were serologically negative
at all time-points.
Discussion
The present experimental trial investigated whether the
efficacy of one-shot vaccination is influenced by the wean-
ing process. Differences between V1 (vaccination three
days before weaning), V2 (vaccination at weaning) and the
PCG (no vacination) were small and mostly statistically
not significant, except for the microscopic lung lesions,
which were lower in V1.
Apart from the transport related to the weaning
process, the piglets in the present study were also trans-
ported to the experimental facilities, a trip that lasted
anywhere from one-half to two hours. In fact, age- and
site-segregated pork production is a complex process
that involves movement of the piglets from the farrow-
ing house to the nursery facilities, which are situated in
different locations [17]. It can be expected, though, that
the stress imposed on the piglets in our study may have
been greater than when the piglets remain on the same
site and are not transported (e.g. in single site farrow-to-
finish pig herds) [18].
Vaccination at the moment of weaning, when the pig-
lets are being handled anyway, is a common practice, as
it can be implemented easily in the daily management of
a pig herd. The pigs of V1 were vaccinated three days
before weaning. This vaccination strategy is also com-
monly practiced by some pig producers in order to avoid
any possible negative effects of the weaning process,
and/or to avoid too much handling or interventions on
the same day [19]. A difference of three days between
Table 2 ADG (± standard deviation SD) of each treatment
group during the three different periods
ADG (±SD) (g/pig/day)
Age range (days) V1 (n = 20) V2 (n = 19) PCG (n = 19) P value
20–48 293 ± 41 299 ± 42 303 ± 55 0.491
48–83 701 ± 116 681 ± 129 718 ± 140 0.442
20–83 519 ± 56 511 ± 66 533 ± 71 0.461
Treatment groups: V1 (vaccinated before weaning, at 18 days of age,
challenge infected), V2 (vaccinated on the day of weaning, at 21 days of
age, challenge infected) and PCG (non-vaccinated, challenge infected). Overall
and pairwise comparisons did not reveal any significant differences between
the groups for the three different periods. D48: experimental infection,
D83: euthanasia
Table 3 Average (± standard deviation SD) values of macroscopic and histopathological lung lesion scores, IF scores, and qPCR
Parametera V1 (n = 20) V2 (n = 19) PCG (n = 19) P value
Macroscopic lung lesions 0.54 ± 0.67A 0.88 ± 1.45A 1.04 ± 2.45A 0.777
Lymphohistiocytic infiltration 2.95 ± 0.50A 3.16 ± 0.58B 3.61 ± 0.59C 0.002
Percentage of air in lung tissue 44.28 ± 14.68A 37.47 ± 17.76B 31.46 ± 14.51C 0.000
IF 1.13 ± 0.54A 1.19 ± 0.79A 1.25 ± 0.70A 0.896
qPCR on BAL fluid 102.94 ± 101.24A 102.76 ± 101.48A 103.23 ± 101.33A 0.616
Treatment groups: V1 vaccinated before weaning, at 18 days of age, challenge infected, V2 vaccinated at weaning, at 21 days of age, challenge infected, and PCG
positive control group i.e. non-vaccinated, challenge infected
Values with different superscript (A-C) in capital letter within a row are significantly different (P ≤ 0.05)
a Macroscopic lung lesion scoring based on Hannan et al. [30]
Lymphohistiocytic infiltration score based on Morris et al. [31]
Percentage of air in lung tissue measured by means of automatic image analysis system (Optimas® 6.5, Media Cybernetics, Silver Spring, USA)
IF scoring based on Kobisch et al. [32]
Values from qPCR on BAL fluid expressed as copies of M. hyopneumoniae/mL
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the two vaccination groups most probably allowed suffi-
cient time for the development of the first and most
critical steps of the immune response prior to the stress
of weaning [20]. At the same time, too great a difference
in age at vaccination was avoided between the piglets in
the V1 and V2 groups. In this sense, the two vaccination
schemes are relevant for the situation in many pig herds.
The experimental infection model used for M. hyop-
neumoniae was similar to that used in previous trials
[21–24]. Challenge infection proved to be successful
since the vast majority of the infected pigs had positive
qPCR values, exhibited the presence of Mycoplasma-like
macroscopic lung lesions at necropsy and were positive
for IF staining. However, the macroscopic lung lesions
observed in the present trial were milder compared to
trials that had been previously conducted using the
same inoculation dose of M. hyopneumoniae F7.2C field
strain, experimental facilities and way of allocation
[23–25]. The precise reasons for this difference are not
known. Based on the macroscopic lung lesion scores,
serology, qPCR testing and IF staining, all the pigs in
the negative control group were negative for M. hyop-
neumoniae throughout the trial, thus confirming that
the study piglets were free of M. hyopneumoniae.
The RDS values in the PCG were similar to those
mentioned in other experimental trials [22, 24]. Com-
pared with the vaccinated groups V1 and V2, the only
differences found in the PCG were numerical. There
were no significant differences in ADG between the
groups. This is mainly due to the high standard devia-
tions observed and the limited numbers of pigs. ADG
was measured, but it was not considered an important
parameter for this experimental study. In vaccination
trials under field conditions however, in which many
more animals can be included, ADG is an important
parameter.
Group V1 had the lowest numbers of macroscopic and
histopathological lung lesions, and the lowest IF scores
when compared to groups V2 and PCG. Nevertheless,
significant differences between groups V1, V2 and PCG
were only obtained for the histopathological lung lesions.
This was confirmed by the results of the percentage of
air parameter in the lung tissue measured by means of
an automatic image analysis system. The statistically
significant differences between groups V1, V2 and PCG
proved that M. hyopneumoniae vaccination is effective
in reducing lymphohistiocytic infiltration and increasing
the percentage of air in the lung. This reduction of the
lymphohistiocytic infiltration scores in the vaccinated
groups is in accordance with previous experimental trials
[22, 24]. The less severe histopathological lesions may be
due to a modulation of the immune response in vacci-
nated animals. It has been shown that vaccination with a
bacterin against M. hyopneumoniae reduces the infiltra-
tion of macrophages in the lung tissue [26].
Although lower qPCR values were recorded in the
vaccinated groups when compared to the PCG, it was
not possible to conclude whether vaccination was associ-
ated with the reduced bacterial load in the lungs, since
the differences between the groups were only numerical.
However, the detection of M. hyopneumoniae in the
BAL fluid of groups V1 and V2 confirms that vaccin-
ation alone is not able to prevent colonization of the
pig’s respiratory tract [4, 22, 24].
The pigs of groups V1, V2 and PCG were seronegative
for M. hyopneumoniae on the day of transportation to
the experimental facilities. At the time of inoculation,
40 % of the pigs in each of the vaccinated groups V1 and
V2 had seroconverted. This is in agreement with other
studies which have reported that vaccination with com-
mercial bacterins induces seroconversion rates ranging
from 30 to 100 % [4, 27]. At necropsy, all the pigs in
groups V1 and V2 were seropositive, while the percent-
age of pigs that had seroconverted in group PCG was
95 %.
Overall, no firm conclusions could be made as to
whether group V1 performed better than groups V2 and
PCG, since only the microscopic lung lesions were
significantly lower in the pigs in group V1. Further
research under field conditions is necessary to elucidate
the possible effect of weaning on the efficacy of one-shot
M. hyopneumoniae vaccination. Field trials make it pos-
sible to include more animals and to study the entire
course of M. hyopneumoniae infections up to the time
of slaughter.
Conclusions
In conclusion, the differences between the vaccinated
groups V1 and V2 were small and mostly statistically not
significant. Thus, no firm conclusions could be made as
to whether the process of weaning had a negative impact
on the efficacy of vaccinating against M. hyopneumoniae.
A future field trial could possibly provide further insight
on the same topic.
Table 4 Percentage of seropositive pigs in the different groups
at different time-points during the trial
Days of age V1 (n = 20) V2 (n = 19) PCG (n = 19)
21a 0 0 0
48b 40 40 0
83c 100 100 95
Treatment groups: V1 (vaccinated before weaning, at 18 days of age,
challenge infected), V2 (vaccinated on the day of weaning, at 21 days of
age, challenge infected), PCG (non-vaccinated, challenge infected) and NCG
(non-vaccinated, non-challenge infected)
a Day of weaning and transport to the animal facilities of the Faculty of
Veterinary Medicine, Ghent University
b Inoculation time
c Necropsy
Arsenakis et al. BMC Veterinary Research  (2016) 12:63 Page 4 of 7
Methods
Animals
Sixty-five cross-bred piglets (Topigs 20 sows and Pietrain
boars) were purchased from a herd that was free of M.
hyopneumoniae and PRRSV. Sows and fattening pigs of
different age groups in the herd had been repeatedly mon-
itored clinically and serologically, and then by means of
macroscopic pneumonia lung lesions at slaughter, and no
evidence for the presence of M. hyopneumoniae or PRRSV
in the herd was found at 3 weeks of age (day seven), the
piglets were weaned and transported for one-half to two
hours to the animal facilities of the Faculty of Veterinary
Medicine, Ghent University, Belgium. From this point
onwards, all the pigs received ad libitum a commercial,
antibiotic-free feed.
Experimental design and M. hyopneumoniae inoculation
At 14 days of age, prior to purchase, piglets from 20
different litters were individually ear-tagged and ran-
domly allocated to four different groups. The three main
treatment groups were: V1 (vaccinated before weaning,
at 18 days of age and while still on the farm; n = 20), V2
(vaccinated during weaning, at 21 days of age and before
being transported to the experimental facilities; n = 20)
and a non-vaccinated positive control group (PCG;
n = 20). Five pigs were used as a negative control
group, to verify that they remained free of M. hyop-
neumoniae. They were not vaccinated. The pigs in
groups V1 and V2 received a single-shot intramuscu-
lar (i.m.) injection (1 mL) of a commercial M. hyop-
neumoniae bacterin vaccine (Ingelvac MycoFLEX®,
Boehringer Ingelheim Vetmedica). The pigs in PCG
were left untreated and were not injected with a placebo
to simulate field conditions. Upon arrival at the Faculty of
Veterinary Medicine, each group was housed in a different
experimental room equipped with a high efficiency par-
ticulate air filter to avoid possible transmission of the
pathogen between groups.
At 48 days of age, the two vaccinated groups, V1 and
V2, as well as the PCG were challenge infected endo-
tracheally with a 7 mL inoculum containing 107 color
changing units per mL of the virulent M. hyopneumo-
niae F7.2C field strain as described previously [28]. The
pigs in the negative control group were inoculated with
7 mL of sterile culture medium. For the inoculations,
the pigs were anaesthetized by administering a mixture
of Xyl-M® 2 % and Zoletil 100® i.m. at a dose rate of
0.3 mL/kg bodyweight.
All animals were euthanized and necropsied at 83 days
of age. Deep anesthesia was induced by administering
i.m. 0.3 mL/kg of a mixture of Xyl-M® 2 % and Zoletil
100®, followed by exsanguination. The study was ap-
proved by the ethical committee for animal experiments
of the Faculty of Veterinary Medicine, Ghent University
(EC2013/35).
Parameters of comparison
Clinical and performance parameters
Each treatment group was examined daily for a mini-
mum of 15 min for the presence of clinical signs
throughout the entire trial period. Coughing severity
was evaluated in a blinded manner by means of an RDS
on a scale from 0 to 6 [29]. According to that scale: 0
(no coughing), 1 (mild coughing after being encouraged
to move), 2 (mild coughing while at rest), 3 (moderate
coughing after being encouraged to move), 4 (moderate
coughing while at rest), 5 (severe coughing after being
encouraged to move), and 6 (severe coughing while at
rest). The daily RDS values were averaged for the three
following periods: from day 29 until day 47, from day 48
(day of inoculation) until day 83 (day of necropsy), and
from day 29 until day 83.
Individual bodyweights were measured at 20, 48 and
83 days of age to determine the ADG of each treatment
group during the three following periods: from day 20
until day 48, from day 48 until day 83 and from day 20
until day 83.
Macroscopic and histopathological lung lesions, and IF
testing for M. hyopneumoniae
After necropsy, Mycoplasma-like macroscopic lung le-
sions were quantified in a blinded manner using a lung
lesion score diagram [30]. Theoretically, the total lung
lesion scores could range between 0 (absence of lesions)
and 35 (entire lung affected).
Two lung tissue samples per lobe (apical, cardiac and
diaphragmatic) were collected from the right lung of each
pig for histopathology and IF testing. Samples were col-
lected from the edges of the lung lesions, if present [24].
For histopathology, the tissue was fixed in 10 % neutral
buffered formalin and routinely processed and embedded
in paraffin. One slide was made per lobe sample. Using
light microscopy, the severity of peribronchiolar and
perivascular lymphohistiocytic infiltration and nodule for-
mation consistent with M. hyopneumoniae lesions were
scored on a scale from 1 to 5 [31]. Scores 1 and 2 were
classified as lesions not related to Mycoplasma infections.
Scores 3, 4 and 5 were considered to be associated with
Mycoplasma infections (mild, moderate and severe lesions
characteristic of broncho-interstitial (cuffing) pneumonia,
surrounding the bronchioles but extending to the intersti-
tium, with lymphofollicular infiltration and mixed inflam-
matory cell exudates). After three lobes per pig were
investigated, the average score per treatment group was
calculated.
The percentage of lung area occupied by air (percent-
age air) was examined by means of an automatic image
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analysis system (Optimas® 6.5, Media Cybernetics, Silver
Spring, USA). This percentage is inversely proportional
to the severity of peribronchiolar and perivascular
lymphohistiocytic infiltration in the lung tissue and
the amount of intrabronchiolar – intrabronchial exud-
ate. An average percentage per treatment group was
calculated [28].
A direct IF assay was performed to assess the presence
of M. hyopneumoniae in the lungs. The scores given
could range from 0 to 3: 0 (no IF), 1 (limited IF), 2
(moderate IF), and 3 (intense IF) [32].
qPCR and bacteriological examination
During necropsy, BAL fluid was collected from the left
part of the lungs before the tissue samples for histopath-
ology and IF were taken [21]. The recovered fluid was
divided into two aliquots, immediately cooled to 4 °C,
and then stored at −70 °C until analysis. The first aliquot
was used to quantify M. hyopneumoniae organisms by
qPCR [33]. DNA was extracted (Qiagen, Blood and
tissue kit, Belgium) and qPCR was performed using the
CFX96 real-time PCR detection system (Bio-Rad). The
analysis was done in a double-replicate single setting. To
convert the threshold values to the number of organisms,
a tenfold dilution series of M. hyopneumoniae DNA was
used. Values below the last dilution were considered as
negative.
The second aliquot of BAL fluid was used for routine
bacteriological culture to detect the presence of Actino-
bacillus and Haemophilus spp., and other pathogens
which may affect the respiratory tract, such as S. suis, B.
bronchiseptica, P. multocida and T. pyogenes [24].
Serology for M. hyopneumoniae
Blood samples were collected from all pigs at 21, 48 and
83 days of age to measure antibodies against M. hyopneu-
moniae, using a blocking ELISA (IDEIA, M hyopneumo-
niae EIA kit, Oxoid, UK) [12]. Sera with optical density
(OD) values < 50 % of the ODbuffer-control were considered
positive, while sera with OD values ≥ 50 % of the ODbuffer-
control were considered negative.
Statistical analysis
The statistical analysis was performed on groups V1, V2
and PCG. Pigs of the negative control group (n = 5)
were not included, as they were only employed to en-
sure that the animals remained free of M. hyopneumo-
niae throughout the experiment. The RDS data were
analyzed using repeated measures analysis of variance
(ANOVA). Levene’s test was used to assess the homo-
geneity of the variances between the different groups.
The ADG, macroscopic and histopathological lung le-
sions, percentage of air in the lungs, IF testing and
qPCR were analyzed with a non-parametric Kruskal-
Wallis ANOVA. These five continuous variables did
not fulfill the criteria for homogeneity of variances.
Statistical results were considered significant when the
P-values were ≤ 0.05 (two-sided test). The statistical
package SPSS 21.0 for Windows (SPSS 21, SPSS Inc.,
IL, USA) was used to analyze the data.
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